Quantcast The Story Behind the Development of NexVax2 | NFCA
Skip Navigation Links

The Story Behind the Development of NexVax2

Share |

 
9/28/2012

You may have heard of Nexvax2, the “celiac vaccine” currently undergoing clinical trials in the US and around the world. (If you haven't, read this announcement.) It’s an exciting breakthrough, and one that has been more than 20 years in the making.

To offer some perspective, Bob Anderson, MBChB, PhD, FRACP, Chief Scientific Officer at ImmunsanT, Inc, the pharmaceutical company behind NexVax2, wrote an article explaining the history and research findings that led to the development of this potential vaccine.

To get a glimpse of the process that led scientists to where they are today, read:

Transforming celiac disease from a digestive disease to an immune disease: and restoring tolerance to gluten in celiac disease

Note: NFCA maintains the position that views and information presented on articles and websites we link to are those of the authors, and not necessarily those of NFCA.
 

<< Back to Research News


 

 
 
  • Have you or your family members been diagnosed?
    Complete our celiac disease symptoms checklist today to find out if you are at risk of having celiac disease or non-celiac gluten sensitivity ('gluten sensitivity').  We can help improve your quality of life!
  • Stay Informed!
    Join our monthly newsletter to receive news, updates, and tips for healthy gluten-free living and information about celiac disease. Sign-up for the monthly e-mail newsletter